Royalty Pharma annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Royalty Pharma Debt-to-Equity Ratio Growth & History (RPRX)
Royalty Pharma's debt-to-equity ratio was 0.92 for fiscal 2025.
View full Royalty Pharma company overviewRoyalty Pharma annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.92 | 0.19 | +25.45% |
| 2024 | 2024-12-31 | 0.74 | 0.13 | +20.98% |
| 2023 | 2023-12-31 | 0.61 | −0.14 | −18.56% |
| 2022 | 2022-12-31 | 0.75 | 0.05 | +7.90% |
| 2021 | 2021-12-31 | 0.69 | 0.10 | +17.80% |
| 2020 | 2020-12-31 | 0.59 | −0.43 | −42.13% |
| 2019 | 2019-12-31 | 1.02 | — | — |
Royalty Pharma quarterly debt-to-equity ratio
Q4.19
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.92 | 0.07 | +8.37% |
| Q1 2026 | 2026-03-31 | 0.90 | 0.12 | +15.93% |
| Q4 2025 | 2025-12-31 | 0.92 | 0.19 | +25.45% |
| Q3 2025 | 2025-09-30 | 0.93 | 0.19 | +25.67% |
| Q2 2025 | 2025-06-30 | 0.85 | 0.07 | +8.41% |
| Q1 2025 | 2025-03-31 | 0.78 | 0.16 | +25.17% |
| Q4 2024 | 2024-12-31 | 0.74 | 0.13 | +20.98% |
| Q3 2024 | 2024-09-30 | 0.74 | 0.10 | +15.93% |
| Q2 2024 | 2024-06-30 | 0.78 | 0.05 | +7.35% |
| Q1 2024 | 2024-03-31 | 0.62 | −0.10 | −14.15% |
| Q4 2023 | 2023-12-31 | 0.61 | −0.14 | −18.56% |
| Q3 2023 | 2023-09-30 | 0.64 | −0.04 | −6.30% |
| Q2 2023 | 2023-06-30 | 0.73 | 0.04 | +6.36% |
| Q1 2023 | 2023-03-31 | 0.73 | 0.02 | +3.55% |
| Q4 2022 | 2022-12-31 | 0.75 | 0.05 | +7.90% |
| Q3 2022 | 2022-09-30 | 0.68 | 0.00 | +0.00% |
| Q2 2022 | 2022-06-30 | 0.68 | 0.12 | +21.95% |
| Q1 2022 | 2022-03-31 | 0.70 | 0.11 | +18.32% |
| Q4 2021 | 2021-12-31 | 0.69 | 0.10 | +17.80% |
| Q3 2021 | 2021-09-30 | 0.68 | 0.09 | +15.09% |
| Q2 2021 | 2021-06-30 | 0.56 | −0.07 | −11.03% |
| Q1 2021 | 2021-03-31 | 0.59 | — | — |
| Q4 2020 | 2020-12-31 | 0.59 | −0.43 | −42.13% |
| Q3 2020 | 2020-09-30 | 0.59 | — | — |
| Q2 2020 | 2020-06-30 | 0.63 | — | — |
| Q4 2019 | 2019-12-31 | 1.02 | — | — |
Royalty Pharma debt-to-equity ratio trends
Over the last five fiscal years, Royalty Pharma's debt-to-equity ratio increased from 0.59 to 0.92, a change of 0.34. The latest reported quarter, Q2 2026, shows 0.92.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Royalty Pharma source filings ↗